Sigma Planning Corp Buys 10,247 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Sigma Planning Corp boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 21.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 58,874 shares of the company's stock after acquiring an additional 10,247 shares during the quarter. Sigma Planning Corp's holdings in Hims & Hers Health were worth $1,740,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Summit Securities Group LLC bought a new stake in Hims & Hers Health during the 4th quarter worth about $38,000. UMB Bank n.a. grew its holdings in Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after acquiring an additional 933 shares during the last quarter. Fifth Third Bancorp grew its holdings in Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after acquiring an additional 961 shares during the last quarter. Tsfg LLC bought a new stake in Hims & Hers Health during the 1st quarter worth about $46,000. Finally, US Bancorp DE grew its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after acquiring an additional 1,508 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Down 3.1%

Shares of HIMS stock opened at $50.44 on Wednesday. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The firm has a fifty day moving average of $53.89 and a 200-day moving average of $41.38. The company has a market capitalization of $11.29 billion, a price-to-earnings ratio of 73.11, a P/E/G ratio of 1.91 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm's revenue was up 110.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 EPS. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In related news, insider Irene Becklund sold 8,485 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $506,978.75. Following the sale, the insider directly owned 712 shares of the company's stock, valued at approximately $42,542. The trade was a 92.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,572 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $47.82, for a total transaction of $122,993.04. Following the completion of the sale, the insider directly owned 158,165 shares in the company, valued at $7,563,450.30. This represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 633,126 shares of company stock worth $33,717,663 in the last ninety days. 17.71% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HIMS shares. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Piper Sandler restated a "neutral" rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Saturday. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, TD Cowen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating and cut their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $39.58.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.